Cormedix Financials - Benzinga

Cormedix Inc

CRMDNASDAQ

Trade with Public

Trade with Public

$8.28

0.080.98%

At close: Aug 21, 5:00 PM EST

$8.43

0.232.82%

Pre-Market: 8:38 AM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Cormedix Financials

Cormedix (CRMD) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

CorMedix Stock Jumps on Strong DefenCath Sales

CorMedix Q2 earnings beat estimates as sales more than doubled, DefenCath revenue grew, and the company reaffirmed 2026 sales guidance.

Vandana Singh

PRO
Cormedix Q2 EPS $0.29 Beats $0.25 Estimate, Sales $101.931M Beat $95.621M Estimate

Benzinga Newsdesk

PRO
Cormedix Affirms FY2026 Sales Guidance of $325.000M-$345.000M vs $334.089M Est

Cormedix (NASDAQ:CRMD) affirms FY2026 sales outlook from $325.000 million-$345.000 million to $325.000 million-$345.000 million vs $334.089 million estimate.

Benzinga Newsdesk

CorMedix Stock Jumps As DefenCath Fuels Q1 Beat, 2026 Outlook Raised

CorMedix raises 2026 guidance after Q1 revenue surges on strong DefenCath demand and higher profitability.

Vandana Singh

PRO
Cormedix Raises FY2026 Sales Guidance from $300.000M-$320.000M to $325.000M-$345.000M vs $308.224M Est

Cormedix (NASDAQ:CRMD) raises FY2026 sales outlook from $300.000 million-$320.000 million to $325.000 million-$345.000 million vs $308.224 million estimate.

Benzinga Newsdesk

PRO
Cormedix Q1 Adj. EPS $0.43 Beats $0.36 Estimate, Sales $127.427M Beat $105.017M Estimate

Cormedix (NASDAQ:CRMD) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.36 by 16.22 percent. This is a 43.33 percent increase over earnings of $0.30 per share from the same

Benzinga Newsdesk